B. E. Chen

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial

Bingshu E. Chen, T. Nielsen, K. Gelmon, 2015, British Journal of Cancer.

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Bingshu E. Chen, H. Eich, V. Diehl, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario.

Bingshu E. Chen, M. Brouwers, C. Booth, 2013, Current oncology.

Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial

K. Davison, V. Kukreti, M. Crump, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16.

E. Eisenhauer, D. LeBrun, D. Tu, 2016, Gynecologic oncology.

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Bingshu E. Chen, W. Parulekar, K. Pritchard, 2020, Breast Cancer Research and Treatment.

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.

K. Strasser-Weippl, P. Goss, W. Parulekar, 2018, European journal of cancer.

The economic impact of the transition from branded to generic oncology drugs.

Bingshu E. Chen, K. Ding, D. Tu, 2016, Current oncology.